Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 210

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 210
---
/2021 15,000 290,550 — — 01/01/2022 30,000 581,100 — — 01/04/2023 45,000 871,650 — — 01/04/2024 75,000 1,452,750 — — Patrick O’Brien 01/01/2021 15,000 290,550 — — 01/01/2022 30,000 581,100 — — 01/04/2023 48,750 944,288 — — 01/04/2024 85,000 1,646,450 — — James Hamilton 01/01/2021 12,500 242,125 — — 01/01/2022 27,500 532,675 — — 01/04/2023 45,000 871,650 — — 01/04/2024 75,000 1,452,750 — — Javier San Martin 01/04/2024 — — — — Tracie Oliver 07/01/2022 35,000 677,950 —— — 01/04/2023 375 7,264 —— — 01/04/2024 75,000 1,452,750 —— — Table of Contents 2025 PROXY STATEMENT Executive Compensation 47

(1) RSUs have various vesting parameters but generally vest in four equal annual installments beginning one year from the grant date. (2) Value is based on our Company’s Common Stock closing price of $19.37 on September 30, 2024. (3) The amounts reported for Christopher Anzalone in this column reflect the January 2020, January 2021, July 2022, December 2022, and December 2023 awards that contain performance-based vesting conditions. These awards and their vesting conditions are described above in the “Compensation Discussion and Analysis” under the heading “Equity Compensation" in this year’s proxy statement and in prior proxy statements, as applicable. Table of Contents 2025 PROXY STATEMENT 48

Fiscal 2024 Options Exercises and Stock Vested Table The following table provides information, with respect to the NEOs, concerning options exercised or RSUs or PRSUs vested during fiscal 2024. Option Awards Stock Awards Name Number of Shares Acquired on Exercise Value